0JAV logo

Insmed IncorporatedLSE:0JAV Stock Report

Market Cap US$28.6b
Share Price
n/a
1Y20.2%
7D29.9%
1D30.3%
Portfolio Value
​
View

Insmed Incorporated

LSE:0JAV Stock Report

Market Cap: US$28.6b

Insmed (0JAV) Stock Overview

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details

0JAV fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 65.3% below our estimate of its fair value

Earnings are forecast to grow 67.61% per year

Analysts in good agreement that stock price will rise by 52.7%

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Significant insider selling over the past 3 months


0JAV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW476,166 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
476,166 investors already sharing narratives
View all narratives

Insmed Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Insmed
Historical stock prices
Current Share PriceUS$129.40
52 Week HighUS$214.00
52 Week LowUS$91.59
Beta0.79
1 Month Change9.23%
3 Month Change28.82%
1 Year Change18.78%
3 Year Change479.25%
5 Year Change440.50%
Change since IPO366.14%

Recent News & Updates

Recent updates

Shareholder Returns

0JAVGB BiotechsGB Market
7D31.9%0.2%0.9%
1Y18.8%-5.0%19.6%

Return vs Industry: 0JAV exceeded the UK Biotechs industry which returned -5% over the past year.

Return vs Market: 0JAV matched the UK Market which returned 19.6% over the past year.

Price Volatility

Is 0JAV's price volatile compared to industry and market?
0JAV volatility
0JAV Average Weekly Movement11.0%
Biotechs Industry Average Movement6.6%
Market Average Movement5.1%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0JAV's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JAV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
19881,664Will Lewiswww.insmed.com

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.

Insmed Incorporated Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
0JAV fundamental statistics
Market capUS$28.63b
Earnings (TTM)-US$875.31m
Revenue (TTM)US$1.14b
25.2x
P/S Ratio
-32.7x
P/E Ratio

Is 0JAV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JAV income statement (TTM)
RevenueUS$1.14b
Cost of RevenueUS$188.22m
Gross ProfitUS$949.42m
Other ExpensesUS$1.82b
Earnings-US$875.31m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-4.01
Gross Margin83.46%
Net Profit Margin-76.94%
Debt/Equity Ratio92.9%

How did 0JAV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/08 12:44
End of Day Share Price 2026/08/07 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insmed Incorporated is covered by 43 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neena Bitritto-GargBaird
Eliana MerleBarclays
Anita DushyanthBerenberg